REPL — Replimune Group, Inc.

Is REPL overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Neutral As of November 17, 2026

Replimune Group, Inc. (REPL) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $21.41. The rating moved from Oversold to Neutral on November 17, 2026.

AI analysis

Replimune Group, Inc. (REPL) is a clinical-stage biotech focused on oncolytic immunotherapies; near-term performance will be driven by clinical-readout news flow and financing outcomes. Public information in the provided dataset is limited, so balance-sheet transparency and upcoming catalysts should be monitored closely. Market conditions are currently defensive, which typically constrains upside for small-cap, trial-dependent oncology names, while partnership or acquisition interest from large pharma represents a meaningful upside scenario. Investors should weigh binary clinical risk and likely capital requirements against the long-term potential of the platform.

Key factors

  • Clinical-stage oncolytic immunotherapy platform with multiple pipeline assets that drive binary trial-readout catalysts
  • Dependency on upcoming clinical data and regulatory review for near-term valuation movement
  • Capital intensity and likely need to access the equity or partner markets absent confirmed late-stage success
  • Sector-wide flows favoring large-cap, defensive healthcare names reduce appetite for small-cap biotech risk in the near term
  • M&A appetite in large-cap pharma for specialty oncology assets could provide upside via partnership or acquisition

Risks

  • Clinical trial failure or safety/regulatory setbacks that materially reduce valuation
  • Limited visibility into current cash runway and potential dilutive financing requirements
  • Competitive pressure from other immuno-oncology modalities and established cancer therapies
  • Market volatility and a risk-off macro environment reducing investor interest in speculative biotech stocks
  • Lack of recent public research and social sentiment data increases information asymmetry for investors

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for REPL — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.